Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Default

Display 30 Products per page

Interventional Neurology: Mechanical Thrombectomy Devices

$4,750.00

Mechanical thrombectomy (MT) is an emergency surgical technique used in eligible patients experiencing acute ischemic stroke (AIS) to remove a blood clot in the brain. In 2021, the combined global market for neuroendovascular MT devices was estimated at approximately $706m.
June 14, 2022
Find out more
Drug Delivery: Transdermal Devices

$4,750.00

This chapter provides a discussion of the sales, competitors, drivers, and limiters of the transdermal drug delivery devices market in the areas of cardiovascular disease (CVD; eg angina pectoris and hypertension), neurological disorders (eg attention deficit hyperactivity disorder [ADHD], major depressive disorder [MDD], Alzheimer’s disease, and Parkinson’s disease), hormone replacement therapy (HRT; eg menopause and osteoporosis treatment), and pain management (eg fentanyl- and lidocaine-based chronic pain treatment). Markets covered by this analysis include the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets.
May 26, 2022
Find out more
Neuromodulation: Deep Brain Stimulation and Vagus Nerve Stimulation Devices Market

$4,750.00

This report provides an overview of primary neurological diseases/disorders treated with deep brain stimulation (DBS) and vagus nerve stimulation (VNS), as well as overviews of DBS and VNS neuromodulation technologies, competitors, sales, forecasts, and competitive and market analysis. Markets covered by this analysis comprise the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets.
May 26, 2022
Find out more
Market Spotlight: Overactive Bladder

$1,318.00

This Market Spotlight report covers the Overactive Bladder market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 25, 2022
Find out more
Disease Analysis: Multiple Myeloma
Read More
Multiple myeloma (MM) is a hematological malignancy characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow. The disease represents approximately 1% of all cancers, and 10% of hematological cancers. The hallmarks of MM are high levels of monoclonal (M-) protein, high levels of clonal plasma cells in the bone marrow, and organ damage.
May 25, 2022
Find out more
Market Spotlight: Primary Sclerosing Cholangitis (PSC)

$1,318.00

This Market Spotlight report covers the Primary Sclerosing Cholangitis (PSC) market, comprising key pipeline drugs, recent events and analyst opinion, upcoming events, clinical trials, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast.
May 25, 2022
Find out more
Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)

$1,318.00

This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 25, 2022
Find out more
Market Spotlight: Systemic Lupus Erythematosus (SLE)

$1,318.00

This Market Spotlight report covers the Systemic Lupus Erythematosus (SLE) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 23, 2022
Find out more
Market Spotlight: Hodgkin’s Lymphoma

$1,318.00

This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, a 10-year disease incidence and prevalence forecast, probability of success, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
May 23, 2022
Find out more
Colorectal Cancer KOL Interview – UK

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for colorectal cancer. Key assets highlighted include Avastin/bevacizumab, Erbitux, Vectibix, Mektovi, Braftovi, Cyramza, Lonsurf, Jemperli, Opdivo, Yervoy, Tecentriq, Cosela, Modufolin, fruquintinib, adagrasib, and sotorasib.
May 23, 2022
Find out more
Colorectal Cancer KOL Interview – US, Northeast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for colorectal cancer. Key assets highlighted include Avastin/bevacizumab, Erbitux, Vectibix, Mektovi, Braftovi, Cyramza, Lonsurf, Jemperli, Opdivo, Yervoy, Tecentriq, Cosela, Modufolin, fruquintinib, adagrasib, and sotorasib.
May 23, 2022
Find out more
Disease Analysis: Pulmonary Hypertension
Read More
Pulmonary hypertension (PH) is a life-threatening and often fatal disease characterized by abnormal vascular proliferation and remodeling of the small pulmonary arteries and arterioles, vasoconstriction, and in situ thrombosis. This leads to a progressive increase in pulmonary vascular resistance (PVR) and, ultimately, the development of right ventricular (RV) dysfunction. Cornerstone histopathological features of the PH vasculopathy include intimal thickening, concentric hypertrophy, and perivascular fibrosis of distal pulmonary arterioles.
May 20, 2022
Find out more
Disease Analysis: Triple-Negative Breast Cancer
Read More
Triple-negative breast cancer (TNBC) is a relatively rare breast cancer subtype. It is characterized by the absence of estrogen and progesterone receptors and does not involve the overexpression of HER2. TNBC is associated with poor prognosis, a high risk of local recurrence, and poor disease-free and cancer-specific survival. It accounts for roughly 14% of breast cancers.
May 20, 2022
Find out more
Disease Analysis: HR+/HER2- Breast Cancer
Read More
Hormone receptor-positive (HR+) is the most common breast cancer subtype, with approximately 70% of breast cancers presenting with overexpression of estrogen receptors, progesterone receptors, or both (De Placido and Pronzato, 2015). Overexpression of the hormone receptors allows estrogen and progesterone to drive tumor growth and proliferation. Therefore, endocrine therapy remains the standard treatment for advanced patients with HR+/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
May 20, 2022
Find out more
Disease Analysis: HER2+ Breast Cancer
Read More
Amplification of the HER2/neu oncogene and related genetic elements on chromosome 17 increases HER2 expression and accelerates tumorigenesis. The natural disease progression meant that, historically, women with breast cancer who overexpressed HER2 were found to have significantly shorter disease-free survival and overall survival compared with women without HER2 amplification; however, the introduction of trastuzumab in 1998 drastically changed patient outcomes, to the point where HER2+ breast cancer patients now have the longest median survival of all breast cancer subtypes. HER2 is overexpressed in approximately 20% of breast cancers.
May 20, 2022
Find out more
Market Spotlight: Pancreatic Cancer

$1,318.00

This Market Spotlight report covers the Pancreatic Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 19, 2022
Find out more
Market Spotlight: Neuropathic Pain

$1,318.00

This Market Spotlight report covers the neuropathic pain market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 19, 2022
Find out more
Market Spotlight: Small-Cell Lung Cancer (SCLC)

$1,318.00

This Market Spotlight report covers the Small Cell Lung Cancer (SCLC) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, probability of success, clinical trials, upcoming and regulatory events, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 19, 2022
Find out more
Disease Analysis: Hepatocellular Carcinoma (HCC)
Read More
Liver cancers can be differentiated based on the cell types they affect. The most common form of liver cancer is hepatocellular carcinoma (HCC), which accounts for 80–90% of liver cancer cases. HCC affects hepatocellular cells, or hepatocytes, which are the most abundant cell type in the liver and are responsible for the liver’s primary functions, such as bile production, protein synthesis, and detoxification. This differentiates HCC from other types of liver cancer such as cholangiocarcinoma, which affects the epithelial cells lining the bile ducts, and angiosarcoma, which affects the endothelial cells lining blood vessels of the liver.
May 19, 2022
Find out more
Disease Analysis: Ovarian Cancer
Read More
Ovarian cancer is defined as a group of tumors that originate in the ovaries. Most ovarian cancers are epithelial carcinomas which begin in the tissue surrounding the ovary. Other less common types of ovarian tumors include primary peritoneal, fallopian tube, and malignant germ cell tumors. Ovarian cancer is the fourth most common cancer among women, and is the leading cause of gynecological cancer-related death in women.
May 19, 2022
Find out more
Market Spotlight: Osteoarthritis and Osteoarthritis Pain

$1,318.00

This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 19, 2022
Find out more
Market Spotlight: Opioid-Induced Constipation

$1,318.00

This Market Spotlight report covers the Opioid-Induced Constipation (OIC) market, comprising key marketed and pipeline drugs, clinical trials, probability of success, licensing and asset acquisition deals, and epidemiology data, as well as presenting drug-specific revenue forecasts.
May 19, 2022
Find out more
Disease Analysis: Gastric Cancer
Read More
Stomach or gastric cancer (GC) refers to any cancer arising in the lining of the stomach. The vast majority (95%) of these cancers are adenocarcinomas, and can be further grouped by anatomic origin. The clearest etiological distinction exists between adenocarcinomas of the gastric cardia (the anterior edge of the stomach surrounding the entry point of the esophagus), and those arising in the other anatomical subsites of the stomach – the fundus, body, pylorus, and the antrum. In most cases, gastric adenocarcinomas will begin in the muscularis mucosae and submucosa, then invading deeper lamina of the gastric wall.
May 18, 2022
Find out more
Spinal Motion Preservation Devices Market

$4,750.00

Sales of spinal motion preservation devices totaled $1.7bn in 2019, with sales expected to climb at a CAGR of 2.0% during 2019-2024.
May 18, 2022
Find out more
Disease Analysis: COVID-19 Prevention
Read More
COVID-19 is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that emerged in late 2019 in Wuhan, China. As of October 2021, there have been 245,373,039 confirmed cases of COVID-19, and 4,979,421 deaths globally. SARS-CoV-2 belongs to the coronavirus family, which collectively cause respiratory and intestinal disease in humans and animals, with other prominent members of the family including Middle East respiratory syndrome (MERS) virus and severe acute respiratory syndrome (SARS) virus.
May 17, 2022
Find out more
Market Spotlight: Venous Thromboembolism (VTE)

$1,318.00

This Market Spotlight report covers the Venous Thromboembolism (VTE) market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, probability of success, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
May 13, 2022
Find out more
Market Spotlight: Coronary Artery Disease

$1,318.00

This Market Spotlight report covers the Coronary Artery Disease (CAD) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, probability of success, and 10-year disease prevalence and incidence forecasts, as well as presenting drug-specific revenue forecasts.
May 13, 2022
Find out more
Disease Analysis: Dyslipidemia
Read More
Dyslipidemia refers to any increase or decrease in lipid levels from defined normal parameters, with physicians particularly focusing on the treatment of elevated low-density lipoprotein cholesterol (LDL-C) due to the well-established link between excessively elevated LDL-C and atherosclerosis. As such, LDL-C is a major modifiable risk factor for cardiovascular (CV) disease, one of the world’s leading causes of morbidity and mortality, though differences in LDL particle morphology can also play a role. Other lipid level deviations in dyslipidemia include elevated triglycerides, low levels of high-density lipoprotein cholesterol (HDL-C), elevated total cholesterol, and elevated non-HDL-C, a marker of cholesterol in all atherogenic lipoproteins
May 13, 2022
Find out more
Market Spotlight: Tuberculosis (TB)

$1,318.00

This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals.
May 12, 2022
Find out more
Market Spotlight: Amyotrophic Lateral Sclerosis (ALS)

$1,318.00

This Market Spotlight report covers the Amyotrophic Lateral Sclerosis (ALS) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, a 10-year disease incidence forecast, probability of success, and licensing and acquisition deals.
May 12, 2022
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *